1. Molecular profiling identifies distinct subtypes across TP53 mutant tumors
    Xin Chen et al, 2022, JCI Insight CrossRef
  2. Rational design, synthesis and biological evaluation of dual PARP-1/2 and TNKS1/2 inhibitors for cancer therapy
    Yizhu Xu et al, 2022, European Journal of Medicinal Chemistry CrossRef
  3. Mutations in TP53 or DNA damage repair genes define poor prognostic subgroups in primary prostate cancer
    Cathleen Nientiedt et al, 2022, Urologic Oncology: Seminars and Original Investigations CrossRef
  4. Mapping molecular subtype specific alterations in breast cancer brain metastases identifies clinically relevant vulnerabilities
    Nicola Cosgrove et al, 2022, Nature Communications CrossRef
  5. Therapeutic Targeting of DNA Damage Repair in the Era of Precision Oncology and Immune Checkpoint Inhibitors
    Curtis A. Clark et al, 2023, Journal of Immunotherapy and Precision Oncology CrossRef
  6. BRCA1/2 Reversion Mutations in Patients Treated with Poly ADP-Ribose Polymerase (PARP) Inhibitors or Platinum Agents
    Sourat Darabi et al, 2022, Medicina CrossRef
  7. Cytocidal Antitumor Effects against Human Ovarian Cancer Cells Induced by B-Lactam Steroid Alkylators with Targeted Activity against Poly (ADP-Ribose) Polymerase (PARP) Enzymes in a Cell-Free Assay
    Nikolaos Nikoleousakos et al, 2021, Biomedicines CrossRef
  8. Low Expression of SLC7A11 Confers Drug Resistance and Worse Survival in Ovarian Cancer via Inhibition of Cell Autophagy as a Competing Endogenous RNA
    Yao Ke et al, 2021, Frontiers in Oncology CrossRef
  9. PARP inhibitor olaparib induced differential protein expression in cervical cancer cells
    Jyotika Rajawat et al, 2023, Journal of Proteomics CrossRef
  10. BRCA2 Frameshift Mutation in de novo Small-Cell Neuroendocrine Carcinoma of the Prostate: A Case Report
    Keisuke Okubo et al, 2023, Case Reports in Oncology CrossRef